FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug
The FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New information shows that the ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] Northeast Bank Q3 FY26 slides: record earnings, 5.15% NIM expansion
- [FINANCE] Earnings call transcript: Watsco Q1 2026 beats forecasts, stock dips
- [FINANCE] RenaissanceRe earnings in focus as reinsurance pricing softens
- [FINANCE] JPMorgan’s Dimon Warns Again on Risks of Credit Market Downturn
- [FINANCE] Investors brace for Yum China earnings amid SSS growth concerns
- [FINANCE] Alexandria Real Estate shares fall 10.6% on lower quarterly earnings